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Abstract 
 
The detection of newborn babies with potentially life-threatening, critical congenital heart 
defects (CCHD) before they collapse or die remains an important clinical challenge. The 
absence of physical signs and the difficulty assessing mild cyanosis means that the newborn 
baby check misses up to a third of babies. Fetal anomaly ultrasound scanning identifies an 
increasing proportion, but this screen is operator-dependent and therefore highly variable; 
although some units report very high detection rates, overall most babies with CCHD are still 
missed.  
Pulse oximetry screening (POS) is an additional test that meets the criteria for universal 
screening. POS increases overall detection of CCHD to over 90% and also identifies babies 
with non-cardiac, hypoxaemic conditions (such as congenital pneumonia, early-onset sepsis 
and pulmonary hypertension), which are usually included in the false positives. 
There is a wealth of published data on POS, both in a research setting and more recently in 
routine clinical practice, and consideration of POS is becoming increasingly widespread 
particularly among high-income countries. But a degree of controversy still remains and 
debate continues regarding the most appropriate time to screen, the most effective 
screening pathway and screening outside the well-baby nursery. So, should all newborn 
babies be screened with POS, if so, when and where should screening take place, what 
saturations are acceptable and which conditions are we trying to identify? 
This review will look at the available evidence and try to suggest the way forward for those 
considering its introduction into their clinical practice. 
 
Critical congenital heart defects 
The definition of CCHDs is inconsistent in the literature which makes comparisons difficult.1 
Many authors suggest that lesions which are either duct-dependent (and therefore 
susceptible to acute collapse or death when the ductus closes) or those causing death or 
requiring urgent intervention in the neonatal period, should be described as critical (see 
table 1).1 The incidence of CCHDs depends on the definition used but is estimated to be 
between 1-1.8 per 1000 livebirths or 15–25% of all CHDs.1,2  
 
 
Screening for CCHD 
As the majority of CCHDs are amenable to intervention, it is these that are the primary 
target of screening. Delay in diagnosis may lead to collapse resulting in a worse outcome 
and so timely diagnosis is an urgent clinical priority.1,2 Diagnosis before birth is the ideal 
solution, allowing for planned delivery and immediate, appropriate intervention but 
antenatal anomaly ultrasound screening, although improving, has a variable detection rate 
and still misses most CCHDs.1 Physical examination screening is also fraught with difficulty as 
many target conditions do not have murmurs or other physical signs and often appear 
healthy until imminent collapse.1 Hypoxaemia or lower oxygen saturations are a feature of 
the majority of CCHDs but the cyanosis is often mild and clinically undetectable even by 
experienced clinicians.  Pulse oximetry is an accurate, simple, painless method of measuring 
oxygen saturations which may be used to detect those babies with CCHD and the concept of 
using this method of screening was first described over 15 years ago. Several recent large 
European studies3-6 and one study from China,7 have clearly demonstrated the test accuracy 
of pulse oximetry screening (POS). A systematic review in 2012 reported an overall 
sensitivity of 76.5% and a specificity of 99.9%.8  POS has also been shown to be cost 
effective9  and acceptable to both clinical staff and parents.10  
POS has recently been adopted as national policy in a number of countries (including the 
USA11 and the Nordic countries12) and many others (including the UK) are considering its 
introduction. 
Despite this positive response to the possibility of POS, there remain a number of important 
issues which still generate debate.13,14 The precise screening pathway or algorithm used in 
studies varies, both in timing of screening and the nature of the saturation data resulting in 
a positive test. The number of test positive (and false positive) babies identified also varies 
significantly, raising concern about overwhelming clinical services, particularly paediatric 
cardiology  which may have to deal with increases in echocardiograms for babies identified 
by screening. Other concerns include the provision of POS for babies born outside hospital 
and for those born at high altitude where oxygen saturations are naturally lower.  
Another interesting and important finding in many studies is that babies with serious, 
potentially life-threatening, non-cardiac, hypoxaemic condition such as respiratory or 
infective disorders are also identified by POS.3-7 These babies are usually classified as false 
positives, but it is generally accepted that early detection of these babies, before they 
become unwell, is a potential advantage and the label of false positive is perhaps a 
misnomer. 
 
Timing of screening 
This is perhaps the most important question arising from different POS studies. The 
systematic review stated that screening earlier (within 24 hours of age) resulted in a much 
higher false positive rate than later screening (after 24 hours) – 0.5% vs. 0.05% - a ten-fold 
difference.8 This important finding played a key role in the decision by the USA to 
recommend later screening.11 However, it is important to understand that in many 
countries, mothers and babies are discharged before 24 hours and in some, an increasing 
proportion are born at home which makes later screening challenging.  
What is also clear, following careful analysis of the data in studies employing later 
screening,3,4 is that sensitivity seems to be higher with earlier screening14 and later 
screening results in babies with CCHD presenting with symptoms before screening has taken 
place. In two studies, 50% of all babies with CCHD presented before screening took place3,4 
and in one study, 20% of those babies presented with acute collapse3 - which is precisely the 
situation that screening aims to prevent. In addition, it is clear from the POS research 
studies3-7 and from POS in routine clinical practice15,16 that in addition to later screening 
resulting in a reduced number of CCHDs being identified, babies with non-cardiac conditions 
such as pneumonia and early-onset sepsis usually present within 24 hours and may not be 
identified before becoming unwell with later screening. Comparison of reports from the UK 
and the USA (using early and late POS respectively) clearly show the differences that timing 
of screening make. In the UK cohort of 25 859 babies, nine babies with CCHD were detected 
and 165 babies had other potentially serious conditions;15 in the USA cohort of 72 694 
babies only three had CCHD and only 17 had other conditions.16 The false positive rate for 
the USA cohort was much lower (0.04% vs. 0.8%), however the number of screens required 
to detect a case of CCHD was much greater (24 231 screens vs. 2 873 screens to detect one 
CCHD).15 The detection of significant non-cardiac disease was similarly reduced. So, when 
considering the timing of POS, it important to reflect on the available evidence taking timely 
diagnosis of CCHD and the detection of serious non-cardiac disorders into account rather 
than just focusing on the false positive rate. As up to 80% of false positives15 may have a 
clinically significant alternative condition, the identification of these babies is a potentially 
valuable additional benefit of POS. These considerations are becoming increasingly 
important and were reflected in the POS guidelines recently produced by the Nordic 
countries which recommended early screening.12 
 
Saturation results for a positive test 
The majority of POS studies4,6,8 used saturations from only one site – the foot, which gives 
post-ductal saturations. However, more recently, studies3,5,7 have employed saturations 
from two sites – right hand and one foot – giving both pre- and post-ductal saturations. So 
rather than a single absolute saturation leading to the test result, two individual values and 
also the difference between the two, contributes to the result. Although the systematic 
review did not identify a significant difference in sensitivity between the two methods, this 
may be explained by the preponderance of single-measurement studies.8 Careful analysis of 
the raw saturation data shows that post-ductal only measurement would miss a small but 
significant proportion of babies that dual testing would identify.8,13,14 Although a relatively 
small number, when considering screening national populations, this becomes increasingly 
important. 
In studies using pre- and post-ductal saturations3,5,7 there are also subtle differences in the 
parameters for test positivity. The USA algorithm3,,11 defines test positives as <95% in both 
limbs and/or a difference of >3% between the two (see figure 1), whereas the UK definition 
is <95% in either limb and/or a difference of >2% (see figure 2).5,15 These differences are 
small but may result in babies with CCHD being picked up or missed in a very small number 
of cases.15 
Further collection of raw saturation data will help clarify whether these differences are 
important for national screening.  
A further difference between the two was the number of repeat tests (one for the UK and 
two for the USA). Although two repeat tests may reduce the number of false positives, it 
may also increase the delay in establishing a definitive diagnosis. In some cases this delay 
may lead to compromise. 
 
Investigations following a positive test 
In the POS research studies, all test positive babies underwent echocardiography to 
establish the presence or absence of CCHD. If this were rolled out in clinical practice then 
the number of test positives becomes very important, as echo services may be 
overwhelmed. However, in routine screening it has been reported that echocardiography is 
unnecessary if an alternative clinical diagnosis (such as a respiratory or infective problem) 
can be established, reserving echo for those cases where CCHD is strongly suspected or an 
alternative diagnosis cannot be made.13-15 In the UK cohort less than 30% of test positive 
babies underwent echocardiography.15 If early screening is performed then a non-cardiac 
diagnosis is more common and so investigations should be ordered after careful clinical 
assessment focusing on the most likely condition.13-15 
 
Screening outside the hospital 
In countries such as the Netherlands, many babies are born at home or in birthing centres 
and in others such as the UK an increasing proportion are born at home. With homebirths 
the midwife usually leaves 2 or 3 hours after birth which means that for screening to take 
place it is required very early or deferred until the following day, potentially leading to a 
delay. It was a concern that very early screening in the first couple of hours would lead to an 
unacceptably high false positive rate as more healthy babies with transitional circulation 
would test positive. Interestingly, recent studies from the Netherlands17 and the UK18 have 
shown the feasibility of screening homebirths as early as one hour after birth without 
creating a clinically unacceptable number of test positives. The Dutch study algorithm 
utilsed a repeat test on day 2 or 3 whereas the UK study employed day 1 testing only. The 
benefit of the additional test is as yet unclear but may be clarified with time as more babies 
are screened in this way. 
 
Screening at altitude 
Altitude affects the normal oxygen saturations and this will potentially lead to more false 
positives. This is felt to be unlikely at mild altitude but becomes more important at 
moderate to high altitude.14 At present there  are insufficient data to recommend which 
saturations should be used and more studies are required. Again, a balance between 
sensitivity and acceptable false positive rate needs to be identified. 
 
 
 
 False negatives  
POS is not a perfect test for CCHD; the overall sensitivity is 75-80%, so 20-25% of babies with 
CCHD will be missed by this method alone. Coarctation and interruption of the aorta are less 
likely to cause hypoxaemia and are the commonest defects missed,2 although a proportion 
of these defects are detected by POS.2,13 Parents and clinical staff should be made aware of 
the limitations of the test and appropriate counselling and discharge advice should always 
be given. 
It is important to remember that POS is additional to existing screening and not a 
replacement. The added value of POS means 92-95% of CCHD are detected.2 
 
Future initiatives 
As the evidence for POS becomes stronger, more countries are considering its introduction. 
In addition to the USA and Nordic countries, other European countries have recommended 
screening or are engaged in National pilot studies evaluating the feasibility of POS within the 
individual clinical settings. A workgroup of European and North American clinicians are 
developing recommendations for an evidence-based universal screening algorithm.19 
As more and more babies are now being routinely screened the collection of raw saturation 
and outcome data are essential to the refinement of this algorithm. 
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